Clinical Laboratory Improvement Advisory Committee (CLIAC), 14535-14536 [2022-05430]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 50 / Tuesday, March 15, 2022 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
The Board is designed to provide
guidance on extramural scientific
program matters, including the: (1)
Review of extramural research concepts
for funding opportunity
announcements; (2) conduct of
Secondary Peer Review of extramural
research grants, cooperative agreements,
and contracts applications received in
response to the funding opportunity
announcements as it relates to the
Center’s programmatic balance and
mission; (3) submission of secondary
review recommendations to the Center
Director of applications to be considered
for funding support; (4) review of
research portfolios, and (5) review of
program proposals.
Matters To Be Considered: The agenda
will include an update on the Traumatic
Brain Injury (TBI) Research Priorities;
Older Adult Falls Research Priorities;
the Diversity, Equity, Belonging,
Inclusion and Accessibility (DEBIA)
Strategic Plan; and Health Equity.
Agenda items are subject to change as
priorities dictate.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Clinical Laboratory Improvement
Advisory Committee (CLIAC)
Public Participation
Written Public Comment: Written
comments must be received on or before
5:00 p.m., EDT, April 18, 2022, by email
at ncipcbsc@cdc.gov. All written
comments will be included as part of
the meeting minutes.
Oral Public Comment: This meeting
will include time for members of the
public to make an oral comment.
Individuals wishing to pre-register for
public comment must do so by
Wednesday, April 6, 2022, at 5:00 p.m.,
EDT. Those pre-registering for public
comment must also register for the
meeting using the link below.
Oral Public Comment Procedure:
Individuals registered to provide public
comment will be called upon first to
speak based on the order of registration,
followed by others from the public. All
public comments will be limited to two
(2) minutes per speaker.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
SIP22–007, COVID–19 and Women: An
Assessment of Challenges and Lessons
Learned to Enhance Public Health
Emergency Preparedness for Women
and Families.
Date: May 11, 2022
Time: 11:00 a.m.–6:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Jaya
Raman, Ph.D., Scientific Review Officer,
National Center for Chronic Disease
Prevention and Health Promotion, CDC,
4770 Buford Highway, Mailstop S107–
B, Atlanta, Georgia 30341, Telephone:
(770) 488–6511, Email: JRaman@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–05429 Filed 3–14–22; 8:45 am]
[FR Doc. 2022–05431 Filed 3–14–22; 8:45 am]
BILLING CODE 4163–18–P
BILLING CODE 4163–18–P
VerDate Sep<11>2014
21:10 Mar 14, 2022
Jkt 256001
14535
PO 00000
Frm 00096
Fmt 4703
Sfmt 4703
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
for the Clinical Laboratory Improvement
Advisory Committee (CLIAC). This
meeting is open to the public, limited
only by the webcast lines available.
Check the CLIAC website on the day of
the meeting for the web conference link
https://www.cdc.gov/cliac. Time will be
available for public comment.
DATES: The meeting will be held on
April 13, 2022, from 11:00 a.m. to 6:00
p.m., EDT, and April 14, 2022, from
11:00 a.m. to 6:00 p.m., EDT.
ADDRESSES: This is a virtual meeting.
Meeting times are tentative and subject
to change. The confirmed meeting
times, agenda items, and meeting
materials including instructions for
accessing the live meeting broadcast
will be available on the CLIAC website
at https://www.cdc.gov/cliac.
FOR FURTHER INFORMATION CONTACT:
Nancy Anderson, MMSc, MT(ASCP),
Senior Advisor for Clinical Laboratories,
Division of Laboratory Systems, Center
for Surveillance, Epidemiology and
Laboratory Services, Office of Public
Health Scientific Services, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, Mailstop V24–3,
Atlanta, Georgia 30329–4018,
Telephone: (404) 498–2741;
NAnderson@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: This Committee is charged
with providing scientific and technical
advice and guidance to the Secretary,
HHS; the Assistant Secretary for Health;
the Director, CDC; the Commissioner,
Food and Drug Administration (FDA);
and the Administrator, Centers for
Medicare and Medicaid Services (CMS).
The advice and guidance pertain to
general issues related to improvement in
clinical laboratory quality and
laboratory medicine practice and
specific questions related to possible
revision of the Clinical Laboratory
Improvement Amendments of 1988
(CLIA) standards. Examples include
providing guidance on studies designed
to improve safety, effectiveness,
efficiency, timeliness, equity, and
SUMMARY:
E:\FR\FM\15MRN1.SGM
15MRN1
khammond on DSKJM1Z7X2PROD with NOTICES
14536
Federal Register / Vol. 87, No. 50 / Tuesday, March 15, 2022 / Notices
patient-centeredness of laboratory
services; revisions to the standards
under which clinical laboratories are
regulated; the impact of proposed
revisions to the standards on medical
and laboratory practice; and the
modification of the standards and
provision of non-regulatory guidelines
to accommodate technological
advances, such as new test methods, the
electronic transmission of laboratory
information, and mechanisms to
improve the integration of public health
and clinical laboratory practices.
Matters To Be Considered: The agenda
will include agency updates from CDC,
CMS, and FDA. In addition to the
general updates, an update will be
provided on the ongoing CLIAC
workgroups. Presentations and CLIAC
discussion will focus on the future of
laboratory medicine, especially testing
in non-traditional sites. There will be an
extended public comment session
focusing on anticipated changes in
testing practices, personnel issues, and
emerging technologies used in nontraditional testing sites. Agenda items
are subject to change as priorities
dictate.
It is the policy of CLIAC to accept
written public comments and provide a
brief period for oral public comments
pertinent to agenda items. Public
comment periods for each agenda item
are scheduled immediately prior to the
Committee discussion period for that
item. In general, each individual or
group requesting to present an oral
comment will be limited to a total time
of five minutes (unless otherwise
indicated). Speakers should email
CLIAC@cdc.gov or notify the contact
person at least five business days prior
to the meeting date. For individuals or
groups unable to attend the meeting,
CLIAC accepts written comments until
the date of the meeting (unless
otherwise stated). However, it is
requested that comments be submitted
at least five business days prior to the
meeting date so that the comments may
be made available to the Committee for
their consideration and public
distribution. All written comments will
be included in the meeting Summary
Report posted on the CLIAC website.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
VerDate Sep<11>2014
21:10 Mar 14, 2022
Jkt 256001
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–05430 Filed 3–14–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10573 and CMS–
10106]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995 (the
PRA), federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information (including each proposed
extension or reinstatement of an existing
collection of information) and to allow
60 days for public comment on the
proposed action. Interested persons are
invited to send comments regarding our
burden estimates or any other aspect of
this collection of information, including
the necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions,
the accuracy of the estimated burden,
ways to enhance the quality, utility, and
clarity of the information to be
collected, and the use of automated
collection techniques or other forms of
information technology to minimize the
information collection burden.
DATES: Comments must be received by
May 16, 2022.
ADDRESSES: When commenting, please
reference the document identifier or
OMB control number. To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
SUMMARY:
PO 00000
Frm 00097
Fmt 4703
Sfmt 4703
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number: llll, Room C4–
26–05, 7500 Security Boulevard,
Baltimore, Maryland 21244–1850.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, you may make your request
using one of following:
1. Access CMS’ website address at
https://www.cms.gov/Regulations-andGuidance/Legislation/Paperwork
ReductionActof1995/PRA-Listing.
FOR FURTHER INFORMATION CONTACT:
William N. Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION:
Contents
This notice sets out a summary of the
use and burden associated with the
following information collections. More
detailed information can be found in
each collection’s supporting statement
and associated materials (see
ADDRESSES).
CMS–10573 Reform of Requirements
for Long-Term Care Facilities
CMS–10106 Medicare Authorization
to Disclose Personal Health
Information
Under the PRA (44 U.S.C. 3501–
3520), federal agencies must obtain
approval from the Office of Management
and Budget (OMB) for each collection of
information they conduct or sponsor.
The term ‘‘collection of information’’ is
defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA
requires federal agencies to publish a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, before
submitting the collection to OMB for
approval. To comply with this
requirement, CMS is publishing this
notice.
Information Collection
1. Type of Information Collection
Request: Revision of a currently
approved collection; Title of
Information Collection: Reform of
Requirements for Long-Term Care
Facilities; Use: According to our data, as
of April 2, 2021, there were 15,372 LTC
E:\FR\FM\15MRN1.SGM
15MRN1
]]>Agencies
[Federal Register Volume 87, Number 50 (Tuesday, March 15, 2022)]
[Notices]
[Pages 14535-14536]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-05430]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Clinical Laboratory Improvement Advisory Committee (CLIAC)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC
announces the following meeting for the Clinical Laboratory Improvement
Advisory Committee (CLIAC). This meeting is open to the public, limited
only by the webcast lines available. Check the CLIAC website on the day
of the meeting for the web conference link https://www.cdc.gov/cliac.
Time will be available for public comment.
DATES: The meeting will be held on April 13, 2022, from 11:00 a.m. to
6:00 p.m., EDT, and April 14, 2022, from 11:00 a.m. to 6:00 p.m., EDT.
ADDRESSES: This is a virtual meeting. Meeting times are tentative and
subject to change. The confirmed meeting times, agenda items, and
meeting materials including instructions for accessing the live meeting
broadcast will be available on the CLIAC website at https://www.cdc.gov/cliac.
FOR FURTHER INFORMATION CONTACT: Nancy Anderson, MMSc, MT(ASCP), Senior
Advisor for Clinical Laboratories, Division of Laboratory Systems,
Center for Surveillance, Epidemiology and Laboratory Services, Office
of Public Health Scientific Services, Centers for Disease Control and
Prevention, 1600 Clifton Road NE, Mailstop V24-3, Atlanta, Georgia
30329-4018, Telephone: (404) 498-2741; [email protected].
SUPPLEMENTARY INFORMATION:
Purpose: This Committee is charged with providing scientific and
technical advice and guidance to the Secretary, HHS; the Assistant
Secretary for Health; the Director, CDC; the Commissioner, Food and
Drug Administration (FDA); and the Administrator, Centers for Medicare
and Medicaid Services (CMS). The advice and guidance pertain to general
issues related to improvement in clinical laboratory quality and
laboratory medicine practice and specific questions related to possible
revision of the Clinical Laboratory Improvement Amendments of 1988
(CLIA) standards. Examples include providing guidance on studies
designed to improve safety, effectiveness, efficiency, timeliness,
equity, and
[[Page 14536]]
patient-centeredness of laboratory services; revisions to the standards
under which clinical laboratories are regulated; the impact of proposed
revisions to the standards on medical and laboratory practice; and the
modification of the standards and provision of non-regulatory
guidelines to accommodate technological advances, such as new test
methods, the electronic transmission of laboratory information, and
mechanisms to improve the integration of public health and clinical
laboratory practices.
Matters To Be Considered: The agenda will include agency updates
from CDC, CMS, and FDA. In addition to the general updates, an update
will be provided on the ongoing CLIAC workgroups. Presentations and
CLIAC discussion will focus on the future of laboratory medicine,
especially testing in non-traditional sites. There will be an extended
public comment session focusing on anticipated changes in testing
practices, personnel issues, and emerging technologies used in non-
traditional testing sites. Agenda items are subject to change as
priorities dictate.
It is the policy of CLIAC to accept written public comments and
provide a brief period for oral public comments pertinent to agenda
items. Public comment periods for each agenda item are scheduled
immediately prior to the Committee discussion period for that item. In
general, each individual or group requesting to present an oral comment
will be limited to a total time of five minutes (unless otherwise
indicated). Speakers should email [email protected] or notify the contact
person at least five business days prior to the meeting date. For
individuals or groups unable to attend the meeting, CLIAC accepts
written comments until the date of the meeting (unless otherwise
stated). However, it is requested that comments be submitted at least
five business days prior to the meeting date so that the comments may
be made available to the Committee for their consideration and public
distribution. All written comments will be included in the meeting
Summary Report posted on the CLIAC website.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-05430 Filed 3-14-22; 8:45 am]
BILLING CODE 4163-18-P
